ACTIVATION OF SYK TYROSINE KINASE PLAYS A ROLE IN RESISTANCE AGAINST THE SELECTIVE BTK INHIBITOR ONO/GS-4059 IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)

被引：0
|
作者：
Tsukamoto, K. [1 ]
Harriet S, W. [1 ,2 ,3 ]
Sandrine, J. [1 ,3 ]
Dyer, M. J. [1 ,2 ,3 ]
机构：
[1] Univ Leicester, Canc Studies, Leicester, Leics, England
[2] Univ Leicester, Mol & Cell Biol, Leicester, Leics, England
[3] Univ Leicester, Ernest Waudby & Helen Scott Haematol Res Inst, Leicester, Leics, England
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E1372
引用
收藏
页码：563 / 564
页数：2
相关论文
共 50 条
  • [41] Role of hypoxia in Diffuse Large B-cell Lymphoma: Metabolic repression and selective translation of HK2 facilitates development of DLBCL (vol 8, 744, 2018)
    Bhalla, Kavita
    Jaber, Sausan
    Nahid, Nanaji M.
    Underwood, Karen
    Beheshti, Afshin
    Landon, Ari
    Bhandary, Binny
    Bastian, Paul
    Evens, Andrew M.
    Haley, John
    Polster, Brian
    Gartenhaus, Ronald B.
    SCIENTIFIC REPORTS, 2018, 8
  • [42] The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines
    Rodland, Gro Elise
    Melhus, Katrine
    Generalov, Roman
    Gilani, Sania
    Bertoni, Francesco
    Dahle, Jostein
    Syljuasen, Randi
    Patzke, Sebastian
    BLOOD, 2019, 134
  • [43] The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines
    Rodland, Gro Elise
    Melhus, Katrine
    Generalov, Roman
    Gilani, Sania
    Bertoni, Francesco
    Dahle, Jostein
    Syljuasen, Randi G.
    Patzke, Sebastian
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [44] Mivavotinib, a Syk Inhibitor, in Relapsed/Refractory (R/R) Non-GCB Diffuse Large B-Cell Lymphoma (DLBCL) with or without MYD88 and/or CD79 Mutations: A Phase 2 Study
    Karmali, Reem
    Landsburg, Daniel J.
    Westin, Jason
    Leonard, John P.
    Kuriakose, Emil T.
    Sumrow, Bradley James
    Carroll, Susheela
    Albert, Katherine
    Akella, Lalith
    Gordon, Leo, I
    BLOOD, 2022, 140 : 12125 - 12126
  • [45] Selective Targeting Cyclin-Dependent Kinase-9 (CDK9) Downmodulates c-MYC and Induces Apoptosis in Diffuse Large B-Cell Lymphoma (DLBCL) Cells
    Rowland, Taylor
    Paiva, Cody
    Rowley, Joelle
    Chen, Andy
    Drew, Lisa
    Hurlin, Peter
    Chang, Bill H.
    Danilov, Alexey V.
    BLOOD, 2016, 128 (22)
  • [46] Selinexor, a selective inhibitor of nuclear export (SINE) compound shows enhanced anti-tumor activity when combined with either venetoclax or bendamustine in diffuse large B cell lymphoma (DLBCL) mouse models
    Elloul, Sivan
    Chang, Hua
    Klebanov, Boris
    Kashyap, Trinayan
    Werman, Maxwell
    Lee, Margaret
    Landesman, Yosef
    Shacham, Sharon
    Kauffman, Michael
    Friedlander, Sharon Y.
    CANCER RESEARCH, 2016, 76
  • [47] Differential Role of the B-Cell Receptor Pathway in Diffuse Large Cell B Cell Lymphoma: Temsirolimus Has Additive Effects in Combination with the BTK Inhibitor PCI-32765 and PI3K Inhibitor Cal101 but Antagonizes Bortezomib in GCB Subtype
    Zoellner, Anna-Katharina
    Bayerl, Stephan
    Weinkauf, Marc
    Hess, Georg
    Hiddemann, Wolfgang
    Dreyling, Martin H.
    BLOOD, 2011, 118 (21) : 723 - 724
  • [48] New insights into possible HDAC inhibitor resistance in DLBCL - Comment on 'defining cellular responses to HDAC-selective inhibitors reveals that efficient targeting of HDAC3 is required to elicit cytotoxicity and overcome naive resistance to pan-HDACi in diffuse large B cell lymphoma'
    Kiesslich, Tobias
    Mayr, Christian
    Bekric, Dino
    Neureiter, Daniel
    TRANSLATIONAL ONCOLOGY, 2024, 44
  • [49] High-throughput combination screening identifies novel drug-drug pairings for a Bruton's tyrosine kinase inhibitor against the ABC subtype of diffuse large B-cell lymphomas
    Mathews, Lesley A.
    Guha, Rajarshi
    Shinn, Paul
    Young, Ryan M.
    Lim, Kian-Huat
    Keller, Jonathan
    Liu, Dongbo
    Yasgar, Adam
    McKnight, Crystal
    Boxer, Matthew B.
    Duveau, Damien Y.
    Jiang, Jian-Kang
    Michael, Sam
    Mott, Bryan T.
    Patel, Paresma R.
    Leister, William
    Maloney, David J.
    LeClair, Christopher A.
    Rai, Ganesha
    Jadhav, Alit
    Peyser, Brian D.
    Austin, Christopher P.
    Martin, Scott
    Simeonov, Anton
    Ferrer, Marc
    Staudt, Louis
    Thomas, Craig J.
    CANCER RESEARCH, 2013, 73 (08)
  • [50] PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND B-CELL NON-HODGKIN LYMPHOMA (B-NHL)
    Brown, J.
    Harb, W.
    Sharman, J.
    Hill, B.
    Ma, S.
    Miller, T.
    Schreeder, M.
    Barr, P.
    Foran, J.
    Gabrilove, J.
    Kelly
    Burger, Ja
    Barnett, E.
    Marine, J.
    Nava-Parada, P.
    Azaryan, A.
    Mei, J.
    Kipps, T.
    HAEMATOLOGICA, 2013, 98 : 217 - 217
12345